Germany’s Curetis AG has secured €9.6 million in venture capital financing, Bloomberg reports. Roche Venture Fund, the venture capital unit of Swiss drug maker Roche Holding, is the new investor in the developer of diagnostics. The company’s management, including CEO Oliver Schacht, and German venture capital firm CD-Venture Inc. also participated in the fundraising process.
The company’s series A financing round, which now totals €34.1 million, with a total capital raised to date of €36.6 million, was led by Dutch VC firm Forbion Capital Partners. The financing will be used to fund human tests of a system to identify infectious diseases.
Click here for the story from Bloomberg.